Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.
The recommended dose is 30 mcg injected intramuscularly once a week.
Treatment may be started at 7.5 mcg weekly and increased by 7.5 mcg weekly until
the full dose of 30 mcg is reached.
DRUG CLASS AND MECHANISM:
Interferon beta-1a (Avonex) is a protein produced by recombinant DNA
technology using genetically engineered Chinese Hamster Ovary Cells into which
the human interferon beta genes have been introduced. It is used for treating
multiple sclerosis (MS). Interferon beta-1a is designed to be identical to
interferon beta that is naturally produced by various cells in the body.
Interferon beta has antiviral properties and plays a role in regulating the
immune response. The exact mechanism by which interferon beta-1a works in the
body to treat MS is not known. Interferon beta-1a does not cure MS. Rather, it
helps to decrease the number of flare-ups and slows the occurrence of some of
the physical disability that commonly occurs in the disease.